A favorable metabolic and antiatherogenic profile in carriers of CYP21A2 gene mutations supports the theory of a survival advantage in this population.
Hormone research 2009 72 (6): 337-43.
Livadas Sarantis, Dracopoulou Maria, Lazaropoulou Christina, Papassotiriou Ioannis, Sertedaki Amalia, Angelopoulos G Nick, Chrousos George P, Dacou-Voutetakis Catheri
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 22, 2019
- Content source: